See more : Ashford Hospitality Trust, Inc. (AHT-PI) Income Statement Analysis – Financial Results
Complete financial analysis of BioSig Technologies, Inc. (BSGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioSig Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Xinxiang Chemical Fiber Co., Ltd. (000949.SZ) Income Statement Analysis – Financial Results
- Brand Concepts Limited (BCONCEPTS.NS) Income Statement Analysis – Financial Results
- Fleury S.A. (FLRY3.SA) Income Statement Analysis – Financial Results
- Fortnox AB (publ) (FNOX.ST) Income Statement Analysis – Financial Results
- Inchcape plc (IHCPF) Income Statement Analysis – Financial Results
BioSig Technologies, Inc. (BSGM)
About BioSig Technologies, Inc.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.00K | 286.00K | 441.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 57.00K | 199.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 0.00 | 0.00 | 0.00 | 6.80K |
| Gross Profit | 18.00K | 229.00K | 242.00K | -550.00K | -54.35K | -12.40K | -11.70K | -10.48K | -10.48K | 0.00 | 0.00 | 0.00 | -6.80K |
| Gross Profit Ratio | 100.00% | 80.07% | 54.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.09M | 5.82M | 5.60M | 18.14M | 9.74M | 4.37M | 4.76M | 2.65M | 1.24M | 548.00K | 992.21K | 888.95K | 582.53K |
| General & Administrative | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.29M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.41K | 0.00 |
| SG&A | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.36M | 484.13K |
| Other Expenses | 361.00K | 293.00K | 198.00K | 94.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 0.00 | 0.00 |
| Operating Expenses | 28.53M | 27.49M | 33.65M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
| Cost & Expenses | 28.53M | 27.55M | 33.85M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
| Interest Income | 9.00K | 3.00K | 2.00K | 45.00K | 132.75K | 10.90K | 75.00 | 1.00 | 1.30K | 11.03K | 70.06K | 124.17K | 171.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.90K | 75.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 361.00K | 666.00K | 639.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 10.02K | 6.80K |
| EBITDA | -28.15M | -26.97M | -33.21M | -58.63M | -34.42M | -17.25M | -13.11M | -10.73M | -9.45M | -7.85M | -6.22M | -2.25M | -1.14M |
| EBITDA Ratio | -156,394.44% | -9,430.77% | -7,656.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.51M | -27.27M | -33.41M | -59.18M | -34.60M | -17.26M | -12.91M | -11.16M | -12.04M | -7.87M | -6.24M | -2.26M | -1.07M |
| Operating Income Ratio | -158,400.00% | -9,533.22% | -7,576.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -178.00K | 3.00K | 555.00K | 44.00K | 133.20K | 10.90K | 210.54K | -422.91K | 2.58M | -604.80K | -3.57M | -124.17K | -77.76K |
| Income Before Tax | -28.69M | -27.26M | -32.86M | -59.14M | -34.47M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.39M | -1.15M |
| Income Before Tax Ratio | -159,388.89% | -9,532.17% | -7,450.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.00K | -1.49M | -6.97M | -549.05K | 21.79K | -210.54K | 422.91K | -2.58M | 11.03K | 70.06K | 90.86K | 0.00 |
| Net Income | -29.04M | -27.27M | -31.36M | -52.17M | -33.92M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.48M | -1.15M |
| Net Income Ratio | -161,338.89% | -9,535.31% | -7,111.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
| EPS Diluted | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
| Weighted Avg Shares Out | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
| Weighted Avg Shares Out (Dil) | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
BioSig's PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by approximately 66%. Company sees clinical adoption and usage of its novel Near Field Tracking algorithm, proven to reduce ablation time by...
BioSig Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024 Common Stock Will Begin Trading on Split-Adjusted Basis on February 2, 2024
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
Westport, CT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced a workforce reduction, intended to...
BioSig Issues Letter to Shareholders Detailing Technology Innovations and Strategic Focus for 2024
Westport, CT, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today issued its 2023 letter to shareholders to recap recent achievements...
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced...
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Westport, CT, Nov. 9, 2023 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced...
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific IP portfolio includes U.S. and worldwide utility and design patents and pending applications in the U.S., Europe, and Asia-Pacific
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
BioSig AI Sciences Achieves Infrastructure and Technology progress in Development of Generative AI Platform for Hospitals
Westport, CT, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today is providing an update since the launch of BioSig's established...
BioSig Introduces New Subscription Model for PURE EP™ Platform, Offering Quicker Access to Latest Features, Customizations
Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest software advancements in intracardiac signal visualization Cleveland Clinic, the #1 heart center in the Nation, signs on as first subscriber to receive latest...
Source: https://incomestatements.info
Category: Stock Reports